ArticlePediatric dermatology
Treatment Patterns in Pediatric Hidradenitis Suppurativa: Time to Treatment Initiation, Initial Treatment, and Time to Switching.
Article in Pediatric dermatology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHidradenitis suppurativa (HS) causes significant morbidity in children. Treatment patterns across sex, race, and ethnicity in pediatric HS have not been thoroughly evaluated. We aim to characterize treatment patterns in pediatric HS, including (1) time to treatment initiation, (2) first prescribed HS treatment, and (3) time to switching following initial therapy across demographic factors.
methodsWe conducted a real-world, retrospective cohort study of patients < 18 years with a HS diagnosis, using a large U.S. national electronic health record database (2005-2025). Treatments prescribed within 1 year after HS diagnosis were categorized as systemic antibiotics, topicals, hormonal therapies, retinoids, biologics, or procedures.
resultsThe cohort included 6659 children with HS (mean age 12.8 ± 2.8 years at diagnosis), 74.9% female, 37.7% White, and 56.5% non-Hispanic/Latino. Overall, 3.2% of children received biologics. Following HS diagnosis, the mean time to treatment initiation was 15 days. The most common initial treatment was systemic antibiotics plus topical therapies. The mean time on the initial treatment regimen prior to switching was 386 days. Multivariable analyses demonstrated that girls were more likely than boys to receive any treatments, including biologics, except major procedures. Non-White children initiated treatment sooner than White children (1 vs. 17 days, p < 0.0001). Regardless of demographic subgroup, most children remained on their initial HS treatment for a mean duration of approximately a year before switching therapies.
conclusionPediatric HS care is characterized by delayed treatment escalation, antibiotic-dominant initial therapy, and variation in treatment initiation timing across demographic groups.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.